PEMAZYRE dosing and administration — 3 of 5

PEMAZYRE allows simple dose modifications

Tablets are available in 3 strengths (13.5 mg, 9 mg and 4.5 mg) to enable dose modification as needed1

Recommended dose reductions1

Recommended dose

13.5 mg

taken orally once daily for 14 days on, followed by 7 days off therapy

First dose reduction

9 mg

taken orally once daily for 14 days on, followed by 7 days off therapy

Second dose reduction

4.5 mg

taken orally once daily for 14 days on, followed by 7 days off therapy

Permanently discontinue if unable to tolerate PEMAZYRE 4.5 mg once daily1

Adapted from Swiss Professional Information PEMAZYRE® (pemigatinib) on www.swissmedicinfo.ch; ref. 1.


For further information, please refer to the PEMAZYRE Swissmedic Professional Information.1

  • Dose modifications or interruption of dosing should be considered for the management of toxicities1
  • Concurrent use of PEMAZYRE with strong CYP3A4 inhibitors should be avoided and requires dose adjustment1
    • If co-administration with a strong CYP3A4 inhibitor is necessary, the dose of patients who are taking 13.5 mg PEMAZYRE once daily should be reduced to 9 mg once daily and the dose of patients who are taking 9 mg PEMAZYRE once daily should be reduced to 4.5 mg once daily1
Question mark icon

Special populations

Question mark icon

Interaction with other medicinal products and other forms of interaction